ClinicalTrials.gg
CompletedNCT02546700Updated Sep 10, 2026Results posted

A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 2 interventional study of Lebrikizumab and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Hoffmann-La Roche. Completed at 63 sites in 9 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.

Started
2015
the only one that year
Phase 2
4 of 10
none open now
Registered
2nd of 10
by date

Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is the only one that started in 2015, is one of 4 in phase 2, and was the 2nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, or all of them as a file.
02

Study summary

Phase II, randomized, double-blind, placebo-controlled, parallel-group clinical trial of lebrikizumab in participants with COPD and a history of exacerbations who are treated with inhaled corticosteroid (ICS) and at least one long-acting bronchodilator inhaler medication. This study will be conducted to assess the safety, efficacy, and patient-reported outcome (PRO) measures.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of greater than or equal to (>/=) 12 months prior to Visit 1
  • Post-bronchodilator /FVC less than (\<) 0.70 at Visit 1 or 2
  • Post bronchodilator FEV1 \<80% predicted at Visit 1 or 2
  • Documented history of one or more acute COPD exacerbations requiring treatment with systemic and/or antibiotics or hospitalization within 12 months prior to Visit 1
  • Current tobacco smoker or former smoker (having stopped smoking for at least 6 months prior to Visit 1) with a history of smoking >/=10 pack-years (20 cigarettes/day for 10 years)
  • On inhaled corticosteroids (ICS) therapy for >/=6 months prior to Visit 1
  • On an eligible bronchodilator medication for >/=6 months prior to Visit 1
  • Chest X-ray or computed tomography (CT) scan within 6 months prior to Visit 1 or chest X-ray prior to Visit 2 that confirms absence of lung disease besides COPD
  • Demonstrated adherence with background COPD inhaler medication during screening period
  • For female participants of childbearing age, use of single or combined methods for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction or anaphylactic reaction to biologic agent or known to lebrikizumab injection
  • History of pulmonary disease other than
  • Diagnosis of alpha-1-antitrypsin deficiency
  • Lung volume reduction surgery or procedure within 12 months prior to Visit 1
  • Supplemental oxygen requirement >2 liters/minute (L/min) at rest or with exertion
  • Current diagnosis of asthma
  • Participants participating in, or scheduled for, an intensive COPD rehabilitation program
  • Maintenance oral therapy
  • Treatment with systemic corticosteroids within 4 weeks prior to Visit 1 or during screen period
  • Unstable ischemic heart disease or other relevant cardiovascular disorders
  • Use of an immunomodulatory or therapy including monoclonal antibodies (includes anti-interleukin-13 (IL) or anti-IL-4/IL-13 therapy)
  • Body weight \<40 kg
  • Any infection that resulted in hospital admission for >/= 24 hours and/or treatment with oral, intravenous (IV), or intramuscular (IM) antibiotics within 4 weeks prior to Visit 1 or during screening
  • Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening
  • Active parasitic or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
  • Received a within 4 weeks prior to Visit 1 or during screening
  • Active tuberculosis requiring treatment within 12 months prior to Visit 1
  • (HIV) or other known immunodeficiency
  • Hepatitis or known liver cirrhosis
  • (AST), Alanine Aminotransferase (ATL), or total elevation >/=2.0 x (ULN) during screening
  • Clinically significant abnormality on screening (ECG) or laboratory tests
  • History of alcohol or drug abuse
  • Pregnant or lactating
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    Lebrikizumab: Biomarker-high

    Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.

    Drug: Lebrikizumab

  • Experimental
    Lebrikizumab: Biomarker-low

    Lebrikizumab will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.

    Drug: Lebrikizumab

  • Placebo comparator
    Placebo: Biomarker-high

    Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-high.

    Drug: Placebo

  • Placebo comparator
    Placebo: Biomarker-low

    Matching placebo will be administered subcutaneously once in every 4 weeks up to 24 weeks to the participants considered as biomarker-low.

    Drug: Placebo

Interventions

  • Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.

  • DrugPlacebo

    Matching placebo will be administered subcutaneously once in every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12

    Adjusted mean change from baseline in pre-bronchodilator FEV1 (assessed using spirometry) at Week 12 was calculated.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Rate of Moderate or Severe COPD Exacerbation

    A moderate COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to treatment with systemic corticosteroids and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to hospitalization. Adjusted exacerbation rate per year was calculated. Results are reported as a 'Number' representing the unadjusted annualized rate of COPD exacerbations per person-year. The total number of exacerbations observed during the period was defined as starting at the date of randomization and ending at most 172 days after randomization (including data collected during safety follow-up in the case of early drug discontinuation) regardless of adherence to study drug divided by the total patient-weeks at risk divided by 52 weeks per year.

    Time frame: Baseline up to Week 24

  2. Change From Baseline in Post-bronchodilator FEV1 at Week 24

    Adjusted mean change from baseline in post-bronchodilator FEV1 at Week 24 was calculated.

    Time frame: Baseline, Week 24

  3. Change From Baseline in Pre-bronchodilator FEV1 at Week 24

    Adjusted mean change from baseline in pre-bronchodilator FEV1 at Week 24 was calculated.

    Time frame: Baseline, Week 24

  4. Time to First COPD Exacerbation

    COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days. Time to first COPD exacerbation was estimated using Kaplan-Meier analysis.

    Time frame: Baseline up to Week 24

  5. Change From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24

    SGRQ-C was assessed by asking participants to recall their COPD-related experiences and to respond to 40 questions included within three domains: symptoms (7 items), activity (13 items), and impacts (20 items). Overall SGRQ-C score ranged from 0 to 100, where lower score indicated better health-related quality of life. Change from baseline in overall SGRQ-C score at Week 24 was reported.

    Time frame: Baseline, Week 24

  6. Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24

    EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Overall EXACT score was the average of domain scores. It ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in overall EXACT score at Week 24 was reported.

    Time frame: Baseline, Week 24

  7. Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24

    EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Cough and Sputum domain score ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in cough and sputum domain EXACT score at Week 24 was reported.

    Time frame: Baseline, Week 24

  8. Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24

    The BDI scores ranged from 0 (very severe impairment) to 4 (no impairment) for each of 3 domains (functional impairment, magnitude of task, and magnitude of effort) and were summed to determine the BDI total score (0 to 12). The TDI scores ranged from -3 (major deterioration) to +3 (major improvement) for each of the 3 domains (functional impairment, magnitude of task, and magnitude of effort). The sum of all domains yielded the TDI total score (-9 to +9). Change from baseline in BDI/TDI at Week 24 was reported.

    Time frame: Baseline, Week 24

  9. Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab

    This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

    Time frame: Baseline up to Week 36

  10. Minimum Observed Serum Trough Concentration (Cmin) of Lebrikizumab

    This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

    Time frame: Pre-dose (Hour 0) at Weeks 4 and 12, at Week 24

  11. Elimination Half-Life (t1/2) of Lebrikizumab

    Elimination half-life was defined as the time measured for the serum concentration to decrease by one half. This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

    Time frame: Pre-dose (Hour 0) on Day 1 (Baseline) and Weeks 1, 4, 12, 24, 28, and 36

07

Results

Posted Sep 10, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboLebrikizumab
Started154155
Completed144146
Not completed109
Withdrew: Adverse event02
Withdrew: Death11
Withdrew: Lack of efficacy04
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject82

Outcome measures

PrimaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12

Adjusted mean change from baseline in pre-bronchodilator FEV1 (assessed using spirometry) at Week 12 was calculated.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · milliliters (mL)
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 12
milliliters (mL)Placebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) at Week 1246.4 (1.5 to 91.2)51.7 (8.2 to 95.1)-20.1 (-68.0 to 27.8)-8.1 (-56.8 to 40.5)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Mixed Models Analysis · p = 0.8670 · Adjusted mean difference: 5.3 · 95% CI -57.0 to 67.6
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Mixed Models Analysis · p = 0.7308 · Adjusted mean difference: 12.0 · 95% CI -56.4 to 80.3
SecondaryRate of Moderate or Severe COPD Exacerbation

A moderate COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to treatment with systemic corticosteroids and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days that lead to hospitalization. Adjusted exacerbation rate per year was calculated. Results are reported as a 'Number' representing the unadjusted annualized rate of COPD exacerbations per person-year. The total number of exacerbations observed during the period was defined as starting at the date of randomization and ending at most 172 days after randomization (including data collected during safety follow-up in the case of early drug discontinuation) regardless of adherence to study drug divided by the total patient-weeks at risk divided by 52 weeks per year.

Time frame:
Baseline up to Week 24
Reported as:
Number · exacerbations per person-year
Rate of Moderate or Severe COPD Exacerbation
exacerbations per person-yearPlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Rate of Moderate or Severe COPD Exacerbation0.781.070.931.14
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Poisson Regression · p = 0.2679 · Rate ratio: 1.36 · 95% CI 0.79 to 2.36
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Poisson Regression · p = 0.4677 · Rate ratio: 1.23 · 95% CI 0.70 to 2.15
SecondaryChange From Baseline in Post-bronchodilator FEV1 at Week 24

Adjusted mean change from baseline in post-bronchodilator FEV1 at Week 24 was calculated.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mL
Change From Baseline in Post-bronchodilator FEV1 at Week 24
mLPlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Post-bronchodilator FEV1 at Week 2420.6 (-24.5 to 65.6)31.2 (-12.0 to 74.5)-8.3 (-56.5 to 39.9)-10.7 (-60.2 to 38.8)
Statistical analysis
  • Placebo: Biomarker-High vs Placebo: Biomarker-Low · Adjusted mean difference: 10.7 · 95% CI -51.6 to 72.9
  • Lebrikizumab: Biomarker-High vs Lebrikizumab: Biomarker-Low · Adjusted mean difference: -2.4 · 95% CI -71.5 to 66.6
SecondaryChange From Baseline in Pre-bronchodilator FEV1 at Week 24

Adjusted mean change from baseline in pre-bronchodilator FEV1 at Week 24 was calculated.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mL
Change From Baseline in Pre-bronchodilator FEV1 at Week 24
mLPlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Pre-bronchodilator FEV1 at Week 2417.5 (-26.4 to 61.5)46.8 (4.3 to 89.3)-31.4 (-78.3 to 15.5)1.9 (-46.1 to 49.9)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Adjusted mean difference: 29.3 · 95% CI -31.8 to 90.3
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Adjusted mean difference: 33.3 · 95% CI -33.8 to 100.4
SecondaryTime to First COPD Exacerbation

COPD exacerbation was defined as new or increased COPD symptoms (for example, dyspnea, sputum volume, and sputum purulence) for at least 2 consecutive days. Time to first COPD exacerbation was estimated using Kaplan-Meier analysis.

Time frame:
Baseline up to Week 24
Reported as:
Median · days
Time to First COPD Exacerbation
daysPlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Time to First COPD ExacerbationNA (NA to NA)25.9 (24.9 to NA)NA (25.0 to NA)24.9 (24.0 to NA)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Log Rank · p = 0.5233 · Hazard ratio (hr): 1.18 · 95% CI 0.67 to 2.10
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Log Rank · p = 0.3085 · Hazard ratio (hr): 1.30 · 95% CI 0.74 to 2.28
SecondaryChange From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24

SGRQ-C was assessed by asking participants to recall their COPD-related experiences and to respond to 40 questions included within three domains: symptoms (7 items), activity (13 items), and impacts (20 items). Overall SGRQ-C score ranged from 0 to 100, where lower score indicated better health-related quality of life. Change from baseline in overall SGRQ-C score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24
units on a scalePlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Health-Related Quality of Life as Assessed by the Overall Score of the Saint George's Respiratory Questionnaire for COPD (SGRQ-C) at Week 24-5.4 (-8.3 to -2.4)-4.6 (-7.5 to -1.7)-8.8 (-11.9 to -5.7)-2.4 (-5.6 to 0.9)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Adjusted mean difference: 0.7 · 95% CI -3.3 to 4.8
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Adjusted mean difference: 6.4 · 95% CI 1.9 to 10.9
SecondaryChange From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24

EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Overall EXACT score was the average of domain scores. It ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in overall EXACT score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24
units on a scalePlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in COPD Symptoms as Measured by the Overall Score of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT) at Week 24-2.4 (-4.4 to -0.4)-2.4 (-4.5 to -0.3)-1.9 (-4.2 to 0.4)-1.4 (-3.7 to 1.0)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Adjusted mean difference: 0.0 · 95% CI -2.9 to 2.9
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Adjusted mean difference: 0.5 · 95% CI -2.8 to 3.8
SecondaryChange From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24

EXACT comprised of 14-item questionnaire containing four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (3 items). Cough and Sputum domain score ranged from 0 to 100, where higher score indicated a more severe condition. Change from baseline in cough and sputum domain EXACT score at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24
units on a scalePlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Cough and Sputum as Measured by the Cough and Sputum Domain Score of the EXACT at Week 24-4.0 (-6.9 to -1.2)-5.2 (-8.2 to -2.2)-5.6 (-8.9 to -2.3)-2.2 (-5.7 to 1.2)
Statistical analysis
  • Placebo: Biomarker-High vs Lebrikizumab: Biomarker-High · Adjusted mean difference: -1.2 · 95% CI -5.3 to 3.0
  • Placebo: Biomarker-Low vs Lebrikizumab: Biomarker-Low · Adjusted mean difference: 3.4 · 95% CI -1.4 to 8.2
SecondaryChange From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24

The BDI scores ranged from 0 (very severe impairment) to 4 (no impairment) for each of 3 domains (functional impairment, magnitude of task, and magnitude of effort) and were summed to determine the BDI total score (0 to 12). The TDI scores ranged from -3 (major deterioration) to +3 (major improvement) for each of the 3 domains (functional impairment, magnitude of task, and magnitude of effort). The sum of all domains yielded the TDI total score (-9 to +9). Change from baseline in BDI/TDI at Week 24 was reported.

Time frame:
Baseline, Week 24
Reported as:
Mean · ratio
Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 24
ratioPlacebo: Biomarker-HighLebrikizumab: Biomarker-HighPlacebo: Biomarker-LowLebrikizumab: Biomarker-Low
Change From Baseline in Dyspnea as Assessed by the Baseline Dyspnea Index/Transition Dyspnea Index (BDI/TDI) at Week 241.0 ± 2.91.4 ± 2.92.3 ± 2.81.6 ± 3.3
SecondaryPercentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab

This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

Time frame:
Baseline up to Week 36
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab
percentage of participantsLebrikizumab
Percentage of Participants With Anti-Therapeutic Antibody (ATA) to Lebrikizumab13.6
SecondaryMinimum Observed Serum Trough Concentration (Cmin) of Lebrikizumab

This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

Time frame:
Pre-dose (Hour 0) at Weeks 4 and 12, at Week 24
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Minimum Observed Serum Trough Concentration (Cmin) of Lebrikizumab
micrograms per milliliter (mcg/mL)Lebrikizumab
Week 49.09 ± 3.64
Week 1214.7 ± 6.68
Week 2415.2 ± 8.10
SecondaryElimination Half-Life (t1/2) of Lebrikizumab

Elimination half-life was defined as the time measured for the serum concentration to decrease by one half. This outcome measure was planned to be analyzed only in overall lebrikizumab arm.

Time frame:
Pre-dose (Hour 0) on Day 1 (Baseline) and Weeks 1, 4, 12, 24, 28, and 36
Reported as:
Mean · days
Elimination Half-Life (t1/2) of Lebrikizumab
daysLebrikizumab
Elimination Half-Life (t1/2) of Lebrikizumab25.1 ± 7.26

Adverse events

Collected over Baseline up to Week 36. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo2/154 (1.3%)23/154 (14.9%)66/154 (42.9%)
Lebrikizumab1/155 (0.6%)21/155 (13.5%)57/155 (36.8%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPlaceboLebrikizumab
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/15415/155
PneumoniaInfections and infestations3/1543/155
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/1541/155
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders1/1540/155
Pulmonary necrosisRespiratory, thoracic and mediastinal disorders1/1540/155
Respiratory arrestRespiratory, thoracic and mediastinal disorders1/1540/155
DiverticulitisInfections and infestations1/1540/155
InfluenzaInfections and infestations1/1540/155
Atrial fibrillationCardiac disorders1/1540/155
Coronary artery occlusionCardiac disorders1/1540/155
Most frequent other events
Most frequent other events
EventPlaceboLebrikizumab
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders55/15451/155
BronchitisInfections and infestations10/1549/155
NasopharyngitisInfections and infestations7/1547/155

Baseline characteristics

Modified intent-to-treat (mITT) population: all participants who received at least one dose of study treatment, grouped according to the treatment assigned at randomization.

Age, Continuous
Age, Continuous(years)PlaceboLebrikizumabTotal
Mean64.6 ± 7.164.5 ± 7.164.5 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLebrikizumabTotal
Female5858116
Male9697193
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLebrikizumabTotal
Hispanic or Latino131427
Not Hispanic or Latino141140281
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLebrikizumabTotal
American Indian or Alaska Native123
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American8412
White142147289
More than one race325
Unknown or Not Reported000
08

Study locations

63 sites
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • California Medical Research Associates, Inc.
    Northridge, California 91324, United States
  • Palmtree Clinical research Inc
    Palm Springs, California 92262, United States
  • Finlay Medical Research
    Miami, Florida 33126, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Southeast Regional Res Group
    Savannah, Georgia 31405, United States
  • Centex Studies
    Lake Charles, Louisiana 70601, United States
  • The Clinical Research Ctr
    St Louis, Missouri 63141, United States
  • Comprehensive Clinical Research Inc.
    Berlin, New Jersey 08009, United States
  • ISA Clinical Research
    Jamaica, New York 11435, United States
  • Gastonia Pharmaceutical Research
    Gastonia, North Carolina 28054, United States
  • Clinical Research Inst. of Southern Oregon, Pc
    Medford, Oregon 97504, United States
  • S. Carolina Pharmaceutical Research
    Spartanburg, South Carolina 29303, United States
  • Baylor College of Medicine; Ben Taub Hospital- Guntupalli
    Houston, Texas 77030, United States
  • Centex Studies
    Houston, Texas 77058, United States
  • Western Washington Medical Group
    Everett, Washington 98208, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • MultiCare Health Center of Washington
    Tacoma, Washington 98405, United States
  • Centro Médico Dra de Salvo
    Buenos Aires, C1426ABP, Argentina
  • Instituto Ave Pulmo
    Mar del Plata, B7602DCK, Argentina
  • Centro Respiratorio Quilmes
    Quilmes, B1878FNR, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, T4000IAR, Argentina
  • Instituto Del Buen Aire
    Santa Fe, S3000ASF, Argentina
  • Specialized Hospital For Active Treatment of Pneumophthisiatric Diseases; Dept of Pneumonology
    Rousse, 7002, Bulgaria
  • MHC - Sofia, EOOD
    Sofia, 1202, Bulgaria
  • Fifth MHAT - Sofia EAD
    Sofia, 1233, Bulgaria
  • National Multiprofile Transport Hospital Tzar Boris Ill; Clinic of Internal Diseases
    Sofia, 2233, Bulgaria
  • Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
    Stara Zagora, 6000, Bulgaria
  • Medical Center Tara OOD
    Veliko Tarnovo, 5000, Bulgaria
  • McMaster University Medical Centre
    Hamilton, Ontario L8N 3Z5, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • Inspiration Research
    Toronto, Ontario M5T 3A9, Canada
  • Hvidovre Hospital, Lungemedicinsk Afdeling
    Hvidovre, 2650, Denmark
  • Lungemedicinsk afd. L, Bispebjerg Hospital
    København NV, 2400, Denmark
  • Odense Universitetshospital, Lungemedicinsk Forskningsenhed
    Odense C, 5000, Denmark
  • Dr. Kenessey Albert Korhaz Es Rendelointezet; Tudoosztaly (Pulmonolgy Dept )
    Balassagyarmat, 2660, Hungary
  • Petz Aladar Megyei Oktato Korhaz
    Győr, 9024, Hungary
  • Selye János Kórház és Rendel?intézet; Allergológiai Szakrendelés
    Komárom, 2900, Hungary
  • Matrai Állami Gyógyintézet ; Bronchológia
    Mátraháza, 3233, Hungary
  • CRU Hungary Kft
    Miskolc, 3529, Hungary
  • Mohacsi Korhaz
    Mohács, 7700, Hungary
  • Farmakontroll Bt.
    Százhalombatta, 2440, Hungary
  • Markusovszky Egyetemi Oktatokorhaz; Tudogondozo
    Szombathely, 9700, Hungary
  • Centro de Investigacion y Atencion Integral Durango CIAID
    Durango, Durango 34080, Mexico
  • Instituto Jalisciense de Investigacion Clinica S.A. de C.V.
    Santa Cecilia, Jalisco 44700, Mexico
  • Centro Respiratorio de México
    México, Mexico CITY (federal District) 14050, Mexico
  • Oaxaca Site Management Organization
    Oaxaca City, Oaxaca 68000, Mexico
  • Centro Integral Médico SJR SC
    Querétaro, 76800, Mexico
  • Mazowieckie Centrum Badan Klinicznych S.C.
    Grodzisk Mazowiecki, 05-825, Poland
  • Poradnia Pulmonologiczna dla Doroslych
    Lódz, 90-153, Poland
  • MS Clinsearch Specjalistyczny NZOZ Janusz Milanowski Katarzyna Szmygin-Milanowska Spó?ka Jawna
    Lublin, 02-090, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej PROFILAKTYKA Wladyslaw Pierzchala
    Ruda ?l?ska, 41-707, Poland
  • NZOZ Lekarze Specjalisci
    Wroclaw, 54-239, Poland
  • SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
    Saint Petersburg, Sankt-Peterburg 197022, Russia
  • St. Petersburg State Medical University n.a. I.P. Pavlov
    Saint Petersburg, Sankt-Peterburg 197089, Russia
  • FSI Scientific Research Inst
    Moscow, 105077, Russia
  • Central Clinical Hospital #1 of RZhD JCS
    Moscow, 125367, Russia
  • Novosibirsk Municipal Clinical Hospital For Emergency Medicine #2
    Novosibirsk, 630008, Russia
  • State Novosibirsk Regional Clinical Hospital
    Novosibirsk, 630087, Russia
  • LLC Reafan
    Novosibirsk, 630099, Russia
  • LLC Medical Center "Alliance-Biomedical - Russian Group"
    Saint Petersburg, 190068, Russia
  • Siberian State Medical University
    Tomsk, 634050, Russia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Nov 2016, 14 months.

Results were first posted in Sep 2026, 9 years 9 months after primary completion.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 14 months is close to that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Sep 11, 2015
StartActual
Sep 17, 2015
Primary completionActual
Nov 25, 2016
CompletionActual
Nov 25, 2016
Results first posted
Sep 10, 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02546700
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 11, 2015
Start date
Sep 17, 2015
Primary completion
Nov 25, 2016
Completion
Nov 25, 2016
Results posted
Sep 10, 2026
Last update
Sep 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion